<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="479">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04531345</url>
  </required_header>
  <id_info>
    <org_study_id>Covid Cytokine</org_study_id>
    <nct_id>NCT04531345</nct_id>
  </id_info>
  <brief_title>Cytokine Status of Covid-19 Patients</brief_title>
  <official_title>The Cytokine Status of Covid-19 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istanbul Training and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istanbul Training and Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      COVID-19, spreading rapidly all over the world, causes serious morbidity and mortality. In
      severe COVID-19 infections, after pulmonary inflammation, cardiovascular organ failure,
      cytokine storm, hemophagocytosis, septic shock, develops due to uncontrolled hypoxia, and
      isolated organ failure turns into multi-organ failure. It is noteworthy that it causes
      lymphopenia in patients. In the studies, the blood levels of certain inflammatory cytokines,
      interleukin-1β,interleukin-6 and TNF-α, were evaluated. In addition, blood values of a
      limited number of cytokines were investigated similarly in a limited number of studies
      published in our country.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The causative agent of coronavirus 2019 (COVID-19) disease, which started in Wuhan province
      of China in December 2019, was severe acute respiratory failure syndrome coronavirus 2
      (SARS-CoV-2), which quickly spread all over the world and caused a pandemic. COVID-19 can
      cause death with symptoms such as fever, cough, muscle pain, shortness of breath, and
      pneumonia (1). Pulmonary pathology of COVID-19 is diffuse alveolar damage, focal reactive
      hyperplasia of pneumocytes with patchy inflammatory cells, intravascular thrombosis,
      monocyte, macrophage and lymphocyte infiltration into pulmonary spaces. Severe infiltration
      of pulmonary tissue affects alveolar gas exchange. In addition, cardiovascular morbidity,
      tachyarrhythmia and thromboembolic events are observed in 1/5 of the hospitalized patients
      with troponin elevation, which is closely related to mortality. In severe COVID-19
      infections, after pulmonary inflammation, cardiovascular organ failure, cytokine storm,
      hemophagocytosis, septic shock, develops due to uncontrolled hypoxia, and isolated organ
      failure turns into multi-organ failure. It is noteworthy that it causes lymphopenia in
      patients. In the studies , the blood levels of certain inflammatory cytokines,
      interleukin-1β,interleukin-6 and TNF-α, were evaluated. In addition, blood values of a
      limited number of cytokines were investigated in a similar way in a limited number of studies
      published in our country.

      We aimed to study IL-1β, IFN-α2, IFN-γ, TNF-α, MCP-1 (CCL2), IL-6, IL-8 (CXCL8), IL-10,
      IL-12p70, IL-17A, IL-18, IL-23, IL-33 at Covid 19 and healthy volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">October 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cytokine levels of patients</measure>
    <time_frame>1 month</time_frame>
    <description>IL-1β, IFN-α2, IFN-γ, TNF-α, MCP-1 (CCL2), IL-6, IL-8 (CXCL8), IL-10, IL-12p70, IL-17A, IL-18, IL-23, IL-33 levels</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Case Group</arm_group_label>
    <description>Patients with Covid 19 PCR (+) results</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <description>Healthy volunteers</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Flow cytometric analysis</intervention_name>
    <description>IL-1β, IFN-α2, IFN-γ, TNF-α, MCP-1 (CCL2), IL-6, IL-8 (CXCL8), IL-10, IL-12p70, IL-17A, IL-18, IL-23, IL-33 cytokine analysis of COvid-19 patients and healthy volunteers</description>
    <arm_group_label>Case Group</arm_group_label>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who admitted to the emergency department with the complaint of respiratory
        failure, lymphopenia in blood tests and Covid 19 (+) in the PCR tests are case group.

        Also healty volunteers who don't have complaint of respiratory failure, lymphopenia in
        blood tests and Covid 19 (-) in the PCR tests are control group.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with Covid 19 PCR (+) results

        Exclusion Criteria:

          -  Cancer Patients

          -  Patients with known immunodeficiency

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ufuk Oguz Idiz, Assoc. Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istanbul Training and Research Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ufuk Oguz Idiz, Assoc. Prof</last_name>
    <phone>+905062044714</phone>
    <email>oguzidiz@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tahir Talat Yurttas, MD</last_name>
    <phone>+905325835419</phone>
    <email>tahirtalat_yurttas@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Istanbul Training and Reseach Hospital</name>
      <address>
        <city>Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017 Jul;39(5):529-539. doi: 10.1007/s00281-017-0629-x. Epub 2017 May 2. Review.</citation>
    <PMID>28466096</PMID>
  </reference>
  <reference>
    <citation>Hu B, Huang S, Yin L. The cytokine storm and COVID-19. J Med Virol. 2020 Jun 27. doi: 10.1002/jmv.26232. [Epub ahead of print] Review.</citation>
    <PMID>32592501</PMID>
  </reference>
  <reference>
    <citation>Soy M, Keser G, Atagündüz P, Tabak F, Atagündüz I, Kayhan S. Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. Clin Rheumatol. 2020 Jul;39(7):2085-2094. doi: 10.1007/s10067-020-05190-5. Epub 2020 May 30. Review.</citation>
    <PMID>32474885</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 27, 2020</study_first_submitted>
  <study_first_submitted_qc>August 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2020</study_first_posted>
  <last_update_submitted>August 27, 2020</last_update_submitted>
  <last_update_submitted_qc>August 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istanbul Training and Research Hospital</investigator_affiliation>
    <investigator_full_name>Ufuk Oguz Idiz</investigator_full_name>
    <investigator_title>Assoc. Prof.</investigator_title>
  </responsible_party>
  <keyword>interleukin</keyword>
  <keyword>cytokine</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

